Zafgen, Inc. (NASDAQ:ZFGN) is set to announce its earnings results on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.

Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same period in the previous year, the firm earned ($0.55) earnings per share. On average, analysts expect Zafgen to post $-2.1 EPS for the current fiscal year and $-1.39 EPS for the next fiscal year.

Shares of Zafgen, Inc. (NASDAQ:ZFGN) opened at 3.49 on Tuesday. The firm has a 50 day moving average price of $3.52 and a 200 day moving average price of $3.76. The stock’s market capitalization is $95.92 million. Zafgen, Inc. has a one year low of $2.89 and a one year high of $5.46.

TRADEMARK VIOLATION WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/31/zafgen-inc-zfgn-set-to-announce-quarterly-earnings-on-tuesday.html.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Zafgen from a “buy” rating to a “hold” rating in a research note on Saturday, August 26th. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $6.38.

In related news, Director Frances K. Heller bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, October 13th. The stock was purchased at an average cost of $3.90 per share, for a total transaction of $39,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 21.20% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Earnings History for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.